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Abstract
Previous studies have demonstrated that prolonged morphine treatment in vivo induces the
translocation of delta opioid receptors (δORs) from intracellular compartments to neuronal
plasma membranes and this trafficking event is correlated with an increased functional competence
of the receptor. The mechanism underlying this phenomenon is unknown; however chronic
morphine treatment has been shown to involve the activation and hypertrophy of spinal glial cells.
In the present study we have examined whether activated glia may be associated with the enhanced
δOR-mediated antinociception observed following prolonged morphine treatment. Accordingly,
animals were treated with morphine with or without concomitant administration of
propentofylline, an inhibitor of glial activation that was previously shown to block the development
of morphine antinociceptive tolerance. The morphine regimen previously demonstrated to initiate
δOR trafficking induced the activation of both astrocytes and microglia in the dorsal spinal cord as
indicated by a significant increase in cell volume and cell surface area. Consistent with previous data,
morphine-treated rats displayed a significant augmentation in δOR-mediated antinociception.
Concomitant spinal administration of propentofylline with morphine significantly attenuated the
spinal immune response as well as the morphine-induced enhancement of δOR-mediated effects.
These results complement previous reports that glial activation contributes to a state of opioid
analgesic tolerance, and also suggest that neuro-glial communication is likely responsible in part for
the altered functional competence in δOR-mediated effects following morphine treatment.
Background
The opioid system, comprised of multiple highly homol-
ogous receptor families and their endogenous opioid pep-
tide ligands, is fundamental to the modulation of the
sensory and affective aspects of pain [1]. Three classes of
opioid receptors (ORs) have been identified through
molecular and pharmacological techniques, namely the
mu (μ), delta (δ), and kappa (κ) ORs [reviewed by 2, 3].
Morphine, a classical μOR agonist with remarkable anal-
gesic efficacy, is the current gold standard in the clinical
treatment of moderate to severe pain; however, its use in
the management of chronic pain may be restricted by the
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development of analgesic tolerance and the unwanted
side effects associated with dose escalation. As such,
understanding the mechanisms underlying opioid toler-
ance has become the primary focus of an extensive
research effort with the aim of uncovering novel therapeu-
tic strategies to treat persistent, unremitting pain.
A growing body of evidence identifies the δOR as an
instrumental player in the development of morphine-
induced analgesic tolerance [reviewed by 4]. Thus, con-
comitant administration of δOR antagonists with mor-
phine [5-9] or antisense oligodeoxynucleotide treatment
directed against the δOR [10] partially blocked the devel-
opment of tolerance to morphine antinociceptive effects.
In agreement with this data, δOR null mutant mice had a
lower propensity to develop antinociceptive tolerance to
morphine compared to their wild type littermates [11,12].
The mechanism by which δOR modulates μOR analgesic
tolerance is not presently known, however, complex inter-
actions between μ and δORs are likely to be relevant in
eliciting various opioid-induced physiological responses.
For example, direct coupling of μ-δORs in the form of het-
ero-oligomers has been demonstrated in both expression
systems and spinal cord tissue [13], which was proposed
to underlie the antinociceptive synergy between μ and
δOR agonists. We, and others, have also demonstrated
that chronic activation of the μOR induces a translocation
of  δORs from intracellular compartments to neuronal
plasma membranes and this phenomenon is correlated
with an increase in δOR functional competence [14-18].
Taken together, the activation and translocation of δORs
may represent an important intermediary step in the
development of morphine tolerance; however the mecha-
nism underlying this trafficking remains unknown.
Several studies suggest an intimate and interactive rela-
tionship between opioids and glial cells. Once regarded as
mere supports cells for CNS neurons, glial cells are now
recognized as performing vital and complex functions in
response to physiological stressors. Indeed, spinal glial
activation has been observed in a number of pathological
states including Alzheimer's [19,20] and Parkinson's [21]
diseases, HIV-associated dementia [22-24], as well as sev-
eral persistent pain syndromes [25-30]. Moreover, spinal
glial cell activation has been linked to the development of
opioid tolerance. Chronic morphine treatment was
reported to activate microglial [31] and astrocytic [31,32]
cells and to increase pro-inflammatory cytokine levels
[31] in the lumbar spinal cords of tolerant rats. Accord-
ingly, co-administration of a glial modulatory agent with
morphine attenuated the spinal immune response and
inhibited the loss of morphine analgesic potency [31,32],
suggesting that spinal glia may contribute to mechanisms
responsible for opioid tolerance.
In the current study, we aimed to investigate the func-
tional relationship between δORs and glial cells following
prolonged chronic morphine administration. We
employed immunohistochemical techniques as well as a
behavioural nociceptive paradigm to assess whether pro-
longed morphine treatment is associated with the activa-
tion of spinal glial, and if indeed so, whether this spinal
immune response is requisite for the observed enhance-
ment in δOR-mediated antinociception.
Results
Prolonged morphine treatment induces spinal astrocytic 
and microglial hypertrophy
The effects of morphine treatment (5–15 mg/kg every 12
h; s.c.) on spinal astrocytes and microglia were assessed by
fluorescent immunohistochemistry for confocal micros-
copy. Lumbar spinal cord segments from rats treated, or
not, with morphine and/or the glial modulating drug,
propentofylline (10 μg/30  μl; intrathecally [i.t.]), were
processed for fluorescent detection of both GFAP and
OX42, markers of astrocytes and microglia, respectively.
Morphine treatment produced a significant increase in
astrocytic (F3,189 = 23.79, p = 0.0015; Figure 1) and micro-
glial (F3,101 = 8.403, p < 0.0001; Figure 1) cell volume as
compared with saline-treated rats, indicating glial cell
hypertrophy. Similarly, the surface areas of both astrocytic
and microglial cells were significantly greater following
morphine treatment as compared with saline-treated rats
(F3,189 = 18.70, p = < 0.0001 for GFAP; F3,101 = 10.32, p =
< 0.0001 for OX42; Table 1). Chronic intrathecal propen-
tofylline administration effectively attenuated this mor-
phine-induced hypertrophy, inhibiting both the increases
in cell volume and in cell surface area. Propentofylline
administration alone had no effect on astrocytic cell size
as it produced no change in GFAP-immunoreactivity com-
pared with controls. Interestingly, propentofylline alone
significantly increased the cell volumes and surface areas
of OX42-immunoreactive cells, indicating an effect on
microglia which was independent of morphine treatment.
Morphine-induced enhancement in δOR-mediated 
antinociception is attenuated by propentofylline
The acute effects of the selective δOR agonist [D-Ala] 2-
deltorphin II (DLT; 10 μg/30 μl) on thermal nociceptive
thresholds in rats receiving chronic morphine, with or
without the concomitant administration of propentofyl-
line or vehicle are depicted in Figure 2. Baseline latencies
were similar in all treatment groups, indicating no effect
of pretreatment on normal thermal nociception (Figure
2A). Rats that received prolonged morphine treatment
had significantly higher latencies at 30 minutes post-DLT
injection when compared to rats pretreated with saline
(Treatment F3,15 = 8.739, p < 0.001; Time F5,15 = 19.41, p
< 0.001), indicating a morphine-induced enhancement in
δOR-mediated analgesia. Concomitant treatment of mor-Molecular Pain 2007, 3:7 http://www.molecularpain.com/content/3/1/7
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Detection of GFAP (panel A) and OX42 (panel B) in the dorsal lumbar spinal cords of rats treated, or not, with morphine was  performed by fluorescent immunohistochemistry and photomicrographs were acquired by confocal microcopy Figure 1
Detection of GFAP (panel A) and OX42 (panel B) in the dorsal lumbar spinal cords of rats treated, or not, with morphine was 
performed by fluorescent immunohistochemistry and photomicrographs were acquired by confocal microcopy. Displayed are 
representative three dimensional images of immunoreactive cells from rats receiving intrathecal saline (i, vi), morphine and 
intrathecal saline (ii, vii), morphine and intrathecal propentofylline (iii, viii), or intrathecal propentofylline alone (iv, ix). Mor-
phine treatment produced a significant increase in both astrocytic and microglial cell volumes as compared with control. This 
hypertrophy was attenuated by coadministration of morphine with propentofylline. While propentofylline alone had no effect 
on GFAP-immunostaining, it significantly enhanced OX42-immunoreactive cell size. Data represent means ± s.e.m. for n = 12–
20 cells per rat from n = 3 rats per group. Statistical analyses were performed by a one-way ANOVA followed by Tukey's post-
hoc multiple comparison test. The asterisk denotes significant difference from saline-treated rats. * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001. MS: morphine sulfate; PF: propentofylline; Sal: saline. Scale bar, 30 μm.Molecular Pain 2007, 3:7 http://www.molecularpain.com/content/3/1/7
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phine with propentofylline significantly attenuated the
morphine-induced enhancement in δOR ligand effects.
Animals pretreated with morphine displayed significantly
greater percent maximum possible effect (% M.P.E.) val-
ues than did saline-treated animals (F3,20 = 6.700, p =
0.0026; Figure 2B). The enhancement in DLT-mediated
analgesia following morphine treatment was blocked
when animals were co-treated with propentofylline. These
animals displayed % M.P.E.s similar to control animals,
indicating no change in δOR activity. Chronic administra-
tion of propentofylline alone had no effect on the analge-
sic effects of DLT, yielding % M.P.E.s similar to control
animals.
Discussion
Opioid agonists are highly efficacious analgesics; however
their clinical use is limited by the incidence of adverse
effects, particularly the development of analgesic toler-
ance following repeated use. A growing body of evidence
identifies an important role for the δOR in modulating
morphine tolerance [5-10] and this phenomenon may
involve the trafficking of δORs from internal stores toward
the neuronal plasma membrane, thereby enhancing the
effects of δOR-selective ligands [4,14-18,33]. The mecha-
nism by which this contributes to morphine tolerance is
unknown; however recent studies support an active role
for spinal glia following chronic morphine treatment
[31,32]. In the current study, we investigated the relation-
ship between δORs and glial activation and indeed dem-
onstrate a functional role for spinal glia in morphine-
induced changes in δOR agonist effects. Moreover, admin-
istration of a glial inhibitor effectively blocked these
changes in δOR function.
The involvement of spinal glia in the modulation of mor-
phine analgesia has been demonstrated in both preclini-
cal [25,27,31,32,34-36] and clinical [37] studies. We
hypothesized that the recruitment of glial cells is a gradual
response to long-term morphine administration and may
be detectable at time points earlier than those at which
analgesic tolerance is established. We therefore assessed
the spinal immune response using a 48 h morphine dos-
ing schedule; one which has been shown to have substan-
tive effects on δOR trafficking and function [14-16,38].
This dosing regimen does not produce a state of tolerance
[15]; however it may initiate mechanisms involved early
in the cascade of events leading to opioid tolerance. In
developing a means of assessing the three dimensional
structures of GFAP- and OX42-immunoreactive cells, we
observed significant increases in cell volume and surface
area of fluorescent GFAP- and OX42-immunoreactive
cells in the dorsal spinal cord following prolonged mor-
phine treatment. These results are in accordance with pre-
vious studies [31,32] illustrating the recruitment of glia in
the events precipitating opioid tolerance. Morphine-
induced glial hypertrophy was attenuated by co-adminis-
tration with propentofylline. Interestingly, while propen-
tofylline administration alone had no effect on astrocytes,
it produced significant microglial hypertrophy in compar-
ison with saline-treated rats. It is not clear why this occurs,
since the combination of morphine and propentofylline
did not show such an effect. The neuroprotective role of
microglia in the CNS is well known and this cell popula-
tion is very much attuned to its microenvironment,
responding swiftly to even subtle physiological changes
[39]. It is possible that the localized administration of an
exogenous compound into the spinal canal, in the
absence of any 'pathological' events, was sufficient to pro-
duce a microglial response, although such an observation
has not been reported previously [31]. Nevertheless, addi-
tional functional studies are necessary to determine
whether this propentofylline-induced increase in cell size
was indeed accompanied by an inflammatory response.
Despite microglial hypertrophy, however, neither base-
line tail flick latencies nor deltorphin-mediated analgesia
were altered following propentofylline administration
alone, suggesting that this increase in microglial cell size
was not functionally relevant in our study.
Activation of both glial cells and δORs appears to be
important in the mechanisms of morphine tolerance,
however it is unknown whether these two events are
mutually exclusive or if, in fact, they represent important
and related intermediary steps in the development of tol-
Table 1: Cell Surface Area (pixels2)
Saline Saline + MS PF + MS PF
GFAP 41843.41 ±
1603.904 ***
57440.11 ±
1960.131
48338.16 ±
1667.994 **
43235.54 ±
1369.27 ***
OX42 50418.92 ±
2441.907 ***
79908.27 ±
6287.605
55693.48 ±
4137.721 **
67083.38 ±
3756.654
Total cell surface area in pixels2 was calculated from the three dimensional reconstructed images of GFAP- and OX42-immunopositive cells within 
the dorsal spinal cords of rats treated with saline, saline and morphine, propentofylline and morphine, or propentofylline alone. Data represent 
means ± s.e.m. for n = 12–20 cells per rat from n = 3 rats per experimental group. Statistical analyses were performed by one-way ANOVA 
followed by Tukey's post-hoc multiple comparison test. The asterisk denotes significant difference from rats treated with saline and morphine. ** = p 
< 0.01, *** = p < 0.001. MS: morphine sulfate; PF: propentofylline.Molecular Pain 2007, 3:7 http://www.molecularpain.com/content/3/1/7
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The antinociceptive effects of DLT (10 μg, i.t.) were assessed in the tail flick acute thermal pain test Figure 2
The antinociceptive effects of DLT (10 μg, i.t.) were assessed in the tail flick acute thermal pain test. Rats chronically treated 
with morphine exhibited enhanced δOR-mediated analgesia as compared with controls and this enhancement was blocked by 
chronic co-administration of morphine with the glial modulatory agent, propentofylline. All testing was performed 12 h follow-
ing the final morphine injection. A) The latencies to respond with a brisk tail flick were measured prior to and at 10 minute 
intervals following DLT administration for 50 minutes. Three pre-drug latencies were averaged to obtain a baseline latency 
value for each rat. B) Mean tail flick latencies at 30 minutes post-DLT injection were converted to % M.P.E. values. Statistical 
analyses of thermal latencies were performed by two-way ANOVA followed by Bonferroni post-hoc while statistics for trans-
formed % M.P.E. data were accomplished by one-way ANOVA followed by Tukey's post-hoc multiple comparison test. Data 
represent means ± s.e.m. for n = 5–6 rats per group. The asterisk denotes a significant difference from saline-treated rats. * = p 
< 0.05. 0: Baseline prior to drug administration; MS: morphine sulfate; PF: propentofylline.Molecular Pain 2007, 3:7 http://www.molecularpain.com/content/3/1/7
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erance. Previous studies demonstrate that δORs are traf-
ficked from internal stores toward the neuronal plasma
membrane following morphine treatment, correlating
with an increased functional competence of the receptor
[14-16]; however it is not known if the spinal immune
response observed following morphine is requisite for
this δOR trafficking event. Therefore, our second series of
experiments aimed to examine the functional role of spi-
nal glia in morphine-induced changes in δOR function.
Consistent with earlier reports [14,15,40,41], we observed
a significant augmentation in δOR-mediated effects in rats
treated with morphine. This enhancement was effectively
blocked by co-administration of morphine with propen-
tofylline, demonstrating an integral role of spinal glial
activation in the functional changes in δOR.
Taken together with previous reports that glial inhibition
prevents the development of morphine tolerance
[27,31,32], this study provides additional evidence for the
role of δORs in opioid tolerance and suggests that glial
activity may precipitate changes in the δOR, including
receptor trafficking. Glial cell activity has been docu-
mented to modulate the trafficking of ionotropic chan-
nels such as AMPA receptors [42,43]; however the current
study is the first to our knowledge to suggest such a mod-
ulation of a G protein coupled receptor. The precise mech-
anism by which glial-modulated functional changes in
δOR may occur is unclear; however two possible mecha-
nisms include i) increased efficiency with which the recep-
tor couples to intracellular signaling cascades, and/or ii)
enhanced cell surface expression of the receptor. Future
experiments will be required to investigate these possibil-
ities.
Conclusion
In the present study, we demonstrate a relationship
between δOR function and spinal glial activation. Indeed,
prolonged administration of morphine induced the acti-
vation of astrocytic and microglial cells in the lumbar spi-
nal cord, which correlated with enhanced antinociceptive
effectiveness of a δOR agonist. Moreover, attenuation of
glial activation with propentofylline, a glial inhibitor,
attenuated the enhancement of δOR agonist-mediated
effects. These data support an intimate relationship
between glial and opioidergic function and provide
insight into the mechanisms by which opioid analgesic
tolerance develops.
Methods
Animals
Adult male Sprague-Dawley rats (220–300 g; Charles
River, Québec, Canada), were housed in groups of two
with ad libitum access to food and water, and maintained
on a reverse 12/12 h light/dark cycle. All behavioural
experiments were performed during the dark phase of the
cycle, and animals were handled prior to experimentation
in order to reduce stress-related analgesia. All experimen-
tal protocols were approved by the Queen's University
Animal Care Committee, and complied with the policies
and directives of the Canadian Council on Animal Care
and the International Association for the Study of Pain.
Drug treatments
Rats were separated into one of four groups receiving i)
morphine and intrathecal saline, ii) morphine and
intrathecal propentofylline (inhibitor of glial activation),
iii) intrathecal propentofylline alone, or iv) intrathecal
saline alone (control group). Morphine sulfate (MS) was
administered every 12 h by subcutaneous injections of
increasing doses (5, 8, 10, 15 mg/kg in saline; Sabex, King-
ston General Hospital, Kingston, Ontario, Canada). This
treatment protocol was previously shown to induce the
trafficking of δORs from intracellular compartments to
neuronal plasma membranes in cultured cortical neurons
as well as in the spinal cord [14]. Propentofylline and
saline (10 μg/30 μl diluted in saline and 30 μl, respec-
tively; Sigma, St. Louis, MO, USA) were administered by
intrathecal injection via lumbar puncture between the L4
and L5 vertebrae under brief isofluorane anesthesia every
24 hours for 5 days based on drug administration proto-
cols required to block morphine tolerance [31]. Successful
drug placement was confirmed by a vigorous tail flick
upon injection. All experiments were performed 12 hours
following the final morphine injection.
Double-labeling fluorescent immunohistochemistry for 
confocal microscopy
Rats (n = 3 per group) were deeply anesthesized with
sodium pentobarbital (75 mg/kg, i.p.; MTC Pharmaceuti-
cals, Cambridge, Ontario, Canada) and transaortically
perfused with 4% paraformaldehyde (PFA) in 0.1 M phos-
phate buffer (PB; 500 ml, pH 7.4). The spinal cords were
removed by spinal ejection and post-fixed in the above
fixative for 30 minutes at room temperature and cryopro-
tected in 30% sucrose in 0.2 M PB for 48 hours at 4°C.
Lumbar segments were isolated and cut into 40 μm trans-
verse sections on a freezing sledge microtome and col-
lected in 0.1 M Tris buffered saline (TBS; pH 7.4). Free-
floating sections were incubated in a blocking solution
containing 10% NGS, 10% BSA followed by incubation
with a rabbit polyclonal antisera recognizing glial fibril-
lary acidic protein (GFAP; 1:2500 working dilution;
DakoCytomation, Ontario, Canada) to label activated
astrocytes and a mouse monoclonal antisera recognizing
OX42 (1:1000 working dilution; Serotec, NC, USA) to
label CD3/CDIIB receptors on activated microglia. Spinal
cord sections were incubated overnight at 4°C with both
primary antibodies, followed by incubation with goat
anti-mouse and goat anti-rabbit secondary antibodies
(both 1:200 working dilution; Molecular Probes, Invitro-Molecular Pain 2007, 3:7 http://www.molecularpain.com/content/3/1/7
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gen, Ontario, Canada) conjugated to Alexa 594 and Alexa
488 fluorophores, respectively. To assess non-specific
labeling, control sections were processed in the absence of
primary antibodies. Sections were mounted on glass
slides, air-dried, and cover-slipped using Aquamount
(Fisher Scientific, Ontario, Canada).
Immunoreactive cells were visualized in the deep dorsal
horn using the Leica TCS SP2 multi photon confocal
microscope (100 × magnification; Leica Microsystems Inc,
Ontario, Canada) and images acquired and digitalized for
quantitative analysis with Leica Confocal Software.
Twenty-five to thirty-five serial images were captured in
0.75 μm increments throughout the z plane using identi-
cal acquisition parameters and x-y coordinates for each of
12–20 immunoreactive cells per rat for n = 3 rats per
experimental group. The serial images were then stacked
and reconstructed in three dimensions using Image-Pro
Plus v5.0 software (MediaCybernetics, MD, USA). Total
cell volume (in pixels3) and cell surface area (in pixels2)
were calculated for each cell based on the three dimen-
sional cell reconstruction. Statistical analyses were per-
formed using Excel XP (Microsoft, Ontario, Canada) and
Prism 4.01 (Graph Pad, San Diego, CA). The average vol-
ume and surface area for cells within each treatment group
were calculated and expressed as means ± s.e.m. These val-
ues were compared by one-way ANOVA followed by
Tukey's post-hoc multiple comparison test. P values less
that 0.05 were considered significant.
Behavioural tail flick assay
The effects of a selective δOR agonist, DLT (10 μg/30 μl
[i.t.]; Sigma), on thermal nociceptive responses were
assessed using the hot water tail flick assay [15]. The distal
5 cm segment of the rat's tail was immersed in noxious
52°C water, and the latency to a vigorous tail flick was
measured. For n = 6 per group, three baseline latencies
were measured prior to DLT injection in order to deter-
mine the normal nociceptive responses of the animals. A
cut-off latency of four times the average baseline response
threshold was imposed to avoid tissue damage in the
event that the animal became unresponsive following
DLT injection. Rats were then injected intrathecally with
DLT. Thermal latencies were measured every 10 minutes
following drug administration for 50 minutes. The %
M.P.E. of DLT was calculated at the 30 minute time point,
as this time point corresponded with the maximum anal-
gesic effect of DLT.
% M.P.E. = (post-drug latency - baseline) ÷ (cut-off latency
- baseline) × 100
The thermal latencies to respond were analyzed by two-
way ANOVA followed by Bonferroni post-hoc  and the
transformed % M.P.E. data were analyzed by one-way
ANOVA followed by Tukey's post-hoc multiple compari-
son test. All values are expressed as means ± s.e.m. P val-
ues less than 0.05 were considered significant.
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